Pregnancy in rheumatic disease patients

Pregnancy outcomes in women with ankylosing spondylitis: a scoping literature and methodological review

In this scoping review, we sought to summarize the types of outcomes collected in pregnant patients with ankylosing spondylitis (AS), and to identify some methodological limitations related to pregnancy research in these patients. A comprehensive search was done to identify relevant articles in MEDLINE and Embase. We included 21 studies assessing pregnancy outcomes in AS. Most studies reported disease flare during pregnancy, and few reported improved disease activity or stable disease. Disease flare occurred in 25-80% of patients during pregnancy and in 30-100% during the postpartum. There was no increased risk of pre-eclampsia across all studies. Based on two case-control studies, there was an increased risk for prematurity and small for gestational age in AS pregnancies, pooled odds ratio (95% confidence interval) 1.99 (1.30-3.05) and 2.41 (1.22-4.77), respectively. The etiologies of cesarean section were not related to joint issues from AS but were related to other causes like pre-eclampsia and prematurity. Some key methodological issues were related to the study design, selection of study participants, disease classification, choice of control participants, and outcome measures. Based on the current literature review, some key areas for future research should evaluate the disease state at conception, effects of pharmacological treatment for AS during pregnancy, and long-term outcomes of children born to women with AS. The use of pregnancy registers and validated measurement tools in pregnancy will help to improve the state and quality of evidence in this field. Key Points • Disease flare during pregnancy in patients with ankylosing spondylitis (AS) occurred in 25-80% of the cases in the various studies, and in 30-100% of the cases during the postpartum period. • There was an increased risk for prematurity, and no increased risk of pre-eclampsia or small for gestational age. Etiologies of cesarean section were not related to the hip or sacroiliac joint affection of the disease but to other causes like pre-eclampsia and prematurity. • This study provides a comprehensive overview of issues related to research on pregnant women with ankylosing spondylitis (AS). We addressed methodological issues related to the study design, selection of study participants, disease classification, control choice, assessment of outcomes measures, and statistical analysis. • The use of pregnancy registers and validated disease activity measurement tools for pregnancy can enhance pregnancy research in women with AS.

Zearalenone Mycotoxicosis: Pathophysiology and Immunotoxicity

Mycotoxicosis refers to the deleterious pathological effects of different types of toxins produced by some worldwide distributing fungi. Mycotoxins, as secondary metabolites are affecting different organs and systems both in animals and human beings. Zearalenone (ZEA), the well-known estrogenic mycotoxins, is an immunotoxic agent. This macrocyclic beta-resorcyclic acid lactone is mycotoxin procreated as a secondary metabolic byproduct by several types of Fusarium, encompassing Fusarium roseum, Fusarium culmorum, Fusarium graminearum, and different other types. Attributing to its potent estrogenic activity, ZEA has been incriminated as one of the major causes of female reproductive disorders. Thus, the purpose of the present review article is to appraise the pathophysiological consequences and subsequent explore the progress in the research field of zearalenone immunotoxicities.

Peripartum issues in the inflammatory arthritis patient: A survey of the RAPPORT registry

Childbearing women with rheumatoid (RA) and psoriatic arthritis (PsA) have significant peripartum issues. A retrospective anonymous RedCAP survey of peripartum period in females with RA/PsA in the RAPPORT registry was performed. Completed analyses included descriptive statistics, Chi-square and Fisher’s exact test. 162 patients (133 RA/29 PsA) completed the survey (103 women having 234 pregnancies), 164 pregnancies occurring before and 70 pregnancies occurring after diagnosis. Pregnancy outcomes from 103 patients included: 96% live births, 1.9% stillbirths, 23% miscarriages, and 15% therapeutic abortions. A third of patients had fewer children than desired due to disease activity, medications and other reasons. For 63 pregnancies after diagnosis: (1) 49% of pregnancies received pre-conception counseling; (2) 65% described good disease control during pregnancy but 74% flared in the first 3 months postpartum; (3) 79% of pregnancies discontinued IA medications; (4) 35% of pregnancies occurred on biologic therapy at or prior to conception. Gestational age at time of delivery was 37–40 weeks in 58% (33/57) post-arthritis vs 66% (83/126) pre-arthritis pregnancies. No statistically significant differences occurred between pregnancies before or after RA/PsA diagnosis for: pregnancy planning, fertility treatment, pregnancy and labour/delivery complications, birth defect frequency or neonatal complications. Neonatal ICU admissions were significantly lower in pre- compared to post-arthritis pregnancies (3.2% vs 14.5%). No pregnancy complications were noted in 24/54 pregnancies on medications compared to 6/9 pregnancies not on medications. The impact of RA/PsA before, during and after pregnancy varied considerably in this cohort emphasizing the importance of informed-decision making at all stages.

[Pathogenetic features of immunological disorders in women with thyroid peroxidase antibodies presence and their effect on infertility treatment by in vitro fertilization (IVF)]

Autoimmune thyroiditis (AIT) is the most common thyroid disease among women of fertile age. An increase of thyropercosidase antibodies (TPO-Ab) occupies one of the leading positions among other autoantibodies in patients with idiopathic infertility. Stimulation of superovulation in assisted reproductive technology (ART) programs leads to thyroid overstimulation, relative hypothyroxinemia and an increase of thyroid stimulating hormone (TSH) level in women with positive TPO-Ab carrier state, leading to a decrease in the reserve capacity of the thyroid affected by the autoimmune process. There is a large number of studies concerning the effect of autoimmune thyroid diseases on the infertility treatment outcomes in ART programs, but the results are contradictory. One of the hypotheses is that TPO-Ab affect the embryo implantation process in the uterus, based on an imbalance of cytokine production by T-helper type 1, 2, and 17, which are not easy to correct by classical hormone replacement therapy with levothyroxine. Nowadays, the immunological mechanisms of these disorders are not well investigated.

Zearalenone, an estrogenic mycotoxin, is an immunotoxic compound

The aim of this study was to assess the toxic effects of zearalenone (ZEA) on the immune function. Ovariectomised rats were treated daily by gavage with 3.0 mg/kg of ZEA for 28 days. Body weight gain, food consumption, haemotological parameters, lymphoid organs, and their cellularities were evaluated. Moreover, acquired immune responses and macrophage activity were also assessed. ZEA promoted reduction in body weight gain, which is not fully explained by diminished food consumption. Despite no effect on haematological parameters, ZEA caused thymic atrophy with histological and thymocyte phenotype changes and decrease in the B cell percentage in the spleen. With respect to acquired and innate immune responses, no statistically significant differences in delayed-type hypersensitivity were noticed; however, in the ZEA-treated rats, antibody production and peroxide release by macrophages were impaired. The observed results could be related to ZEA activity on ERs; thus, ZEA is an immunotoxic compound similar to estrogen and some endocrine disruptors.